Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23187848 | 0.87 | KIF11 (0.68) | KIF11SIRT2 | |
| SCHEMBL16139243 | 0.85 | KIF11 (0.50) | KIF11SIRT2 | |
| SCHEMBL1906153 | 0.83 | SIRT2 (0.63) | KIF11SIRT2 | |
| SCHEMBL9106215 | 0.77 | KIF11 (0.63) | KIF11 | |
| SCHEMBL14962372 | 0.77 | SIRT2 (0.52) | KIF11SIRT2 | |
| SCHEMBL17933728 | 0.76 | SIRT2 (0.63) | KIF11SIRT2 | |
| SCHEMBL11490946 | 0.76 | KIF11 (0.52) | KIF11SIRT2 | |
| SCHEMBL19154882 | 0.74 | SIRT2 (0.50) | KIF11SIRT2 | |
| SCHEMBL16653155 | 0.73 | KIF11 (0.53) | KIF11 | |
| SCHEMBL98808 | 0.73 | KIF11 (0.53) | KIF11SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3438118-B1 | PEPTIDE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES (JP) | 2023-03-29 | — | — | EP | disclosed |
| US-20230093594-A1 | PANTETHENOYLCYSTEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-03-23 | — | — | US | disclosed |
| CN-108779146-B | Peptide derivatives and uses thereof | 东丽株式会社 | 2022-03-18 | — | — | CN | disclosed |
| US-10792365-B2 | Peptide derivative and use thereof | TORAY INDUSTRIES, INC. (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190038757-A1 | PEPTIDE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2019-02-07 | — | — | US | disclosed |
| EP-3438118-A1 | PEPTIDE DERIVATIVE AND USE THEREOF | Toray Industries, Inc. (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-8329879-B2 | H3LMN compound used as radioactive agent for treatment of liver cancer and manufacturing method thereof | ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2012-12-11 | — | — | US | disclosed |
| US-20110065904-A1 | H3LMN COMPOUND USED AS RADIOACTIVE AGENT FOR TREATMENT OF LIVER CANCER AND MANUFACTURING METHOD THEREOF | ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2011-03-17 | — | — | US | disclosed |
| EP-1311475-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002014267-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10792365-B2 | Peptide derivative and use thereof | NGLY1, NPPA, NPR1 | KIF11 4406/4885SIRT2 3308/4885 |
| US-20190038757-A1 | PEPTIDE DERIVATIVE AND USE THEREOF | NGLY1, NPPA, NPR1 | KIF11 4406/4885SIRT2 3308/4885 |
| US-20110065904-A1 | H3LMN COMPOUND USED AS RADIOACTIVE AGENT FOR TREATMENT OF LIVER CANCER AND MANUFACTURING METHOD THEREOF | L3MBTL3, LIPC, L3MBTL4 | KIF11 1228/4885SIRT2 3263/4885 |
| US-20230093594-A1 | PANTETHENOYLCYSTEINE DERIVATIVES AND USES THEREOF | NQO1, PROC, MPST | KIF11 4388/4885SIRT2 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.